Observational studyJournal of the American Heart Association2014
Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study.
Observational study in Journal of the American Heart Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Pooled it
- Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.Hypertension (Dallas, Tex. : 1979) · 2018Guideline
- Environment-Wide Association Study of Blood Pressure in the National Health and Nutrition Examination Survey (1999-2012).Scientific reports · 2016Pooled it
- Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering.Journal of clinical hypertension (Greenwich, Conn.) · 2019Trial
- Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension.Journal of the American Society of Hypertension : JASH · 2016Trial
- Association of leisure-time aerobic physical activity time with apparent treatment-resistant hypertension: a study based on NHANES database.Biology of sport · 2025Article
- Characterizing apparent treatment resistant hypertension in the United States: insights from the All of Us Research Program.Journal of the American Medical Informatics Association : JAMIA · 2024Article
- Exploring the Spectrum of Comorbidities Associated with Primary Aldosteronism: Insights from a Large Real-World Case-Control Study.Biomedicines · 2024Article
- Effects of baroreflex activation therapy on cardiac function and morphology.ESC heart failure · 2024Article
- Trilogy of drug repurposing for developing cancer and chemotherapy-induced heart failure co-therapy agent.Acta pharmaceutica Sinica. B · 2024Article
- Prevalence, Risk Factors and Cardiovascular Comorbidities of Resistant Hypertension among Treated Hypertensives in a Nigerian Population.Global heart · 2024Article
- Characterization of Individuals With Apparent Resistant Hypertension Using Contemporary Guidelines: Insights From CV-QUIC.Hypertension (Dallas, Tex. : 1979) · 2023Article
- Role of home blood pressure monitoring in resistant hypertension.Clinical hypertension · 2023Review
- Article
- Promise of Physiological Profiling to Prevent Stroke in People of African Ancestry: Prototyping Ghana.Current neurology and neuroscience reports · 2022Review
- Mechanisms of Coronary Ischemia in Women.Current cardiology reports · 2022Review
- Apparent Treatment-Resistant Hypertension Among Stroke Survivors: A Transcontinental Study Assessing Impact of Race and Geography.American journal of hypertension · 2022Article
- Key determinants of long-term post-stroke mortality in Ghana.Journal of the neurological sciences · 2022Article
- Resistance to antihypertensive treatment and long-term risk: The Atherosclerosis Risk in Communities study.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
- Eligibility for Baroreflex Activation Therapy and medication adherence in patients with apparently resistant hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundWomen are more likely than men to develop resistant hypertension, which is associated with excess risk of major adverse outcomes; however, the impact of resistant hypertension in women with ischemia has not been explicitly studied. In this Women's Ischemia Syndrome Evaluation (WISE) analysis, we assessed long-term adverse outcomes associated with apparent treatment-resistant hypertension (aTRH) among women with suspected myocardial ischemia referred for coronary angiography. METHODS AND
resultsWomen (n=927) were grouped according to baseline blood pressure (BP): normotensive (no hypertension history, BP <140/90 mm Hg, no antihypertensive drugs); controlled (BP <140/90 mm Hg and a hypertension diagnosis or on 1 to 3 drugs); uncontrolled (BP ≥140/90 mm Hg on ≤2 drugs); or aTRH (BP ≥140/90 mm Hg on 3 drugs or anyone on ≥4 drugs). Adverse outcomes (first occurrence of death [any cause], nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure or angina) were collected over 10 years of follow-up. Apparent treatment-resistant hypertension prevalence was 10.4% among those with hypertension. Women with aTRH had a greater incidence of adverse outcomes, compared with normotensive women (adjusted hazard ratio [HR], 3.25; 95% confidence interval [CI], 1.94 to 5.43), and women with controlled (HR, 1.77; 95% CI, 1.26 to 2.49) and uncontrolled (HR, 1.62; 95% CI, 1.15 to 2.27) hypertension; outcome differences were evident early in follow-up. Risk of all-cause death was greater in the aTRH group, compared to the normotensive women and women with controlled and uncontrolled hypertension.
conclusionsIn this cohort of women with evidence of ischemia, aTRH was associated with a profoundly increased long-term risk of major adverse events, including death, that emerged early during follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.